Hyundai Bioscience Co., Ltd. (KOSDAQ:048410)

South Korea flag South Korea · Delayed Price · Currency is KRW
13,900
-250 (-1.77%)
Apr 10, 2026, 3:30 PM KST
Market Cap1.36T +139.8%
Revenue (ttm)3.52B -76.6%
Net Income-22.13B
EPS-0.21
Shares Out96.04M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,064,555
Average Volume1,778,845
Open14,430
Previous Close14,150
Day's Range13,890 - 14,600
52-Week Range4,325 - 21,500
Beta1.06
RSI50.16
Earnings DateMay 14, 2026

About Hyundai Bioscience

Hyundai Bioscience Co., Ltd. operates as a biotechnology company. The company provides Vitabrid C12, a vitamin C product that delivers active vitamin C into the skin. It develops Polytaxel, a drug for pancreatic cancer and solid tumors; and CP-COV03 drug for Covid 19. The company was founded in 2000 and is based in Seoul, South Korea. [Read more]

Industry Medical - Pharmaceuticals
Sector Healthcare
Founded 2000
Employees 69
Stock Exchange KOSDAQ
Ticker Symbol 048410
Full Company Profile

Financial Performance

In 2025, Hyundai Bioscience's revenue was 3.52 billion, a decrease of -76.63% compared to the previous year's 15.05 billion. Losses were -22.13 billion, 219.3% more than in 2024.

Financial Statements